Valeant company group chairman and executive vice president resigns
March 3, 2016Medical Communications, Sales and Marketing Valeant, appointed, resignation
In an already troubled week for Valeant Pharmaceuticals, the company has now announced that its group chairman and executive vice …
CHMP recommends Sanofi’s two-dose schedule HPV vaccine
March 3, 2016Research and Development HPV vaccine, MSD, Sanofi Pasteur
Sanofi Pasteur’s and MSD’s vaccine against human papillomavirus (HPV), Gardasil 9, has received a positive opinion from the European Medicine …
Novo says diabetes drug Xultophy cost-effective versus insulin intensification treatment
March 2, 2016Sales and Marketing Novo Nordisk, Xultophy, diabetes
Novo Nordisk says findings show its Tresiba and Victoza combo Xultophy (insulin degludec/liraglutide: IDegLira), is cost-effective compared to insulin intensification …
Bill Griffiths joins NDA group as general manager UK
March 2, 2016Medical Communications NDA Group
Industry veteran Bill Griffiths has joined NDA Group to head up the company’s UK consulting team and NDA’s advisory board. …
FDA approves Gilead’s Odefsey for treatment of HIV-1 infection
March 2, 2016Research and Development, Sales and Marketing Gilead Sciences, HIV, Odefsey
Gilead Sciences has announced that the US Food and Drug Administration (FDA) has approved its TAF-based single tablet regimen Odefsey …
Janssen slams NICE decision on Imbruvica
March 2, 2016Research and Development, Sales and Marketing CLL, Cancer, Cancer Drugs Fund, Janssen, Johnson & Johnson, NICE, imbruvica
Janssen, the R&D arm of pharma major Johnson & Johnson, says it is extremely disappointed following regulator NICE’s announcement that …
Top 10 medicines issued in England by prescription cost in 2014-15
March 2, 2016Research and Development, Sales and Marketing Cost, Humira, NHS, prescription
AbbVie, Humira (adalimumab), £371m. This drug treats a variety of conditions including psoriatic arthritics, Crohn’s disease and ulcerative colitis. The …
Clinton steps up attacks on Valeant in latest campaign advert
March 2, 2016Research and Development, Sales and Marketing Hilary Clinton, Valeant
This is not the first time the pharma industry has drawn the ire of the US presidential hopefuls, but Hilary …
LEO Pharma UK/Ireland appoints new dermatology director
March 2, 2016Medical Communications, Sales and Marketing
LEO Pharma has appointed Michael Hinchy as dermatology director with responsibility for its UK/Ireland affiliate. Michael brings over 16 years …
Chi-Med starts Phase II trial for thyroid cancer drug
March 2, 2016Research and Development Chi-Med
Hutchison China MediTech (Chi-Med) says its unit Hutchison MediPharma (HMP) has initiated mid-stage trials for sulfatinib to treat differentiated thyroid …
Ferring names Aaron Graff CEO of US holding company
March 2, 2016Medical Communications
Swiss fertility treatment company Ferring Pharmaceuticals on Tuesday named Aaron Graff the chief executive of its US unit, Ferring Holding. …
Merck begins late-stage trials of Humira biosimilar
March 2, 2016Research and Development, Sales and Marketing AbbVie, Humira, Merck, biosimilars
Merck has announced the beginning of a global phase III study of its Humira (adalimumb) biosimilar, MSB11022, in chronic plaque …
Wave expands team with new appointments
March 1, 2016Medical Communications
Medical education specialist, Wave, has made five new appointments, which the company says reflects the growth in its business over …
Exelixis signs $200 million licensing deal for cancer drug
March 1, 2016Research and Development, Sales and Marketing Cancer, Cometriq, Exelixis, ipsen
Exelixis has signed a licensing agreement with French biotech firm Ipsen for its cancer drug Cometriq (cabozantinib) for an upfront …
Two Celgene cancer drugs approved in Ireland
March 1, 2016Research and Development, Sales and Marketing Abraxane, Cancer, Celgene, Revlimid, imnovid
Irish regulators have recommended two cancer treatments from Celgene: Imnovid (pomalidomide), in combination with dexamethasone, for previously-treated relapsed and refractory …
Delivering successful new drugs
March 1, 2016Manufacturing and Production, Sales and Marketing AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Pfizer, patents, pharma
Pharma companies are struggling with challenges specific to their industry. Patents for many drugs, that had created massive amounts of …
The future for pharma packaging
March 1, 2016Manufacturing and Production distribution, packaging, research, supply chain
The pharmaceutical packaging market is projected for strong growth through 2020, driven by innovation for new products and materials and …
Lupin to set up manufacturing plant in Japan
March 1, 2016Manufacturing and Production Japan, Lupin, manufacturing
Indian drugmaker Lupin is, via its Japanese unit Kyowa, setting up a manufacturing unit in Japan as part of its …
South Florida Uni begins £875,000 dementia drug research programme
March 1, 2016Manufacturing and Production, Research and Development Alzheimer's
Funding from a consortium worth £875,000 pounds has helped kick start a new dementia drug research program at the University …
Japan approves Astellas hyperphosphatemia drug
March 1, 2016Manufacturing and Production, Research and Development, Sales and Marketing Astellas, Hyperphosphatemia, Japan, Kiklin
Astellas Pharma has received approval from the Ministry of Health, Labour and Welfare in Japan for a supplemental new drug …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
